Takeda Pharmaceutica
4502
End-of-day quote Tokyo - 12/07
3889JPY
-5.24%
Income Statement Evolution
Annual Income Statement Data
Actuals in M JPY Estimates in M JPY
Fiscal Period March 20182019
Sales1 770 5311 763 583
EBITDA437 460391 100
Operating profit (EBIT)--
Pre-Tax Profit (EBT)217 205195 960
Net income186 886142 217
EPS ( JPY )239181
Dividend per Share ( JPY )180180
Yield3,47%4,63%
Announcement Date05/14/2018
06:00am		-
Finances - Leverage
Actuals in M JPY Estimates in M JPY
Fiscal Period March 20182019
Debt610 494584 000
Finance--
Operating income (EBITDA)437 460391 100
Leverage
(Debt/EBITDA)		1,40x1,49x
Capital Expenditure67 005105 603
Book Value Per Share (BVPS)2 557  JPY2 586  JPY
Cash Flow per Share490  JPY408  JPY
Announcement Date05/14/2018
06:00am		-
Balance Sheet Analysis
Financial Ratios
Size 2019e 2020e
Capitalization 3 090 596 M JPY -
Entreprise Value (EV) 3 674 596 M JPY 3 550 163 M JPY
Valuation 2019e 2020e
P/E ratio (Price / EPS) 21,4x 17,9x
Capitalization / Revenue 1,75x 1,72x
EV / Revenue 2,08x 1,97x
EV / EBITDA 9,40x 9,22x
Yield (DPS / Price) 4,63% 4,63%
Price to book (Price / BVPS) 1,50x 1,47x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) - -
operating Leverage (Delta EBIT / Delta Sales) - -
Net Margin (Net Profit / Revenue) 8,06% 9,49%
ROA (Net Profit / Asset) 4,48% 4,25%
ROE (Net Profit / Equities) 6,97% 7,78%
Rate of Dividend 99,3% 82,8%
Balance Sheet Analysis 2019e 2020e
CAPEX / CA   5,99% 7,22%
Cash Flow / Sales 18,2% 20,4%
Capital Intensity (Assets / Sales) 1,80x 2,23x
Financial Leverage (Net Debt / EBITDA) 1,49x 1,19x
Price Earning Ratio
BNA & Dividende